The Pediatric Oncology Department provides specialized, comprehensive care for infants, children, adolescents, and young adults (AYAs) facing cancer. Recognizing that a child's cancer and their response to treatment are unique, our department focuses on curative strategies that prioritize minimizing long-term side effects and preserving quality of life. We integrate the latest Precision Medicine, CAR T-cell therapy, and Proton Therapy protocols, following the gold standards.
The mission of our Pediatric Oncology Department transcends treating the disease; it is to ensure every child has the potential for a healthy, long-lasting life. We operate on a Total Care Model—a philosophy pioneered in pediatric oncology—which encompasses expert clinical treatment, groundbreaking research, and extensive psychological and developmental support.
Children are not small adults. Our specialized team is trained to manage the unique biology of childhood cancers (like Leukemia and Neuroblastoma) and to understand the specific impact treatment has on a developing body (brain, heart, growth plates).
The Pediatric Oncologist leads a dedicated team that includes pediatric surgeons, radiation oncologists, pathologists, and specialists in genetics, ensuring every treatment decision adheres to internationally recognized guidelines (COG, SIOP, NCCN).
We not only focus on achieving high survival rates but also on maximizing quality of life, using risk-based therapy to ensure children with the highest risk receive intensive therapy, while those at lower risk have treatment intensity minimized.
Our services include a full spectrum of treatments tailored to a child's specific cancer, often incorporating novel therapies developed through cooperative group clinical trials.
A highly personalized form of Immunotherapy where the patient's own T-cells are collected, genetically modified ex vivo to express a Chimeric Antigen Receptor (CAR), and re-infused to selectively target and destroy cancer cells (e.g., CD19-positive leukemia).
Immune System Upgrade: We take some of your child's own immune cells, teach them to recognize the cancer cell as an enemy, multiply them into millions, and put them back. These "super-charged" cells actively hunt and eliminate the cancer.
A medical procedure used for high-risk or relapsed cancers (Leukemia, Lymphoma, Neuroblastoma) involving high-dose chemotherapy followed by the infusion of healthy stem cells (autologous or allogeneic) to restore the bone marrow's function.
Bone Marrow Renewal: For very aggressive cancers, we replace the unhealthy, damaged bone marrow with healthy cells, often from a donor or the child themselves. This allows the child to receive the strong therapy needed to fight the cancer.
Uses advanced tumor-profiling techniques to genetically define the patient's specific tumor characteristics and match them with targeted small molecule inhibitors or novel agents.
Pinpointing the Weakness: We use highly detailed genetic tests to find the cancer's "switch." We then use custom medications designed to flip that switch off, stopping the cancer's growth with less impact on the rest of the body.
Our team includes pediatric oncologists, pediatric surgeons, pediatric radiologists, and specialized nurses with additional training in managing childhood cancers and chemotherapy administration.
We integrate Child Life Specialists (using play and art to help children cope), Pediatric Psychologists, and Social Workers from diagnosis through survivorship, addressing the emotional, developmental, and social needs of the patient and family.
We recognize the importance of long-term monitoring for potential side effects (late effects) of treatment, such as cardiac risk or fertility issues. Our dedicated Survivorship Division develops customized surveillance plans to ensure our patients remain healthy decades after treatment completion.
We actively participate in the Children's Oncology Group (COG) and similar research consortia, ensuring our patients benefit from the largest, most successful clinical trials globally, which have elevated pediatric cure rates to over 80% for many types of childhood cancer.
We proactively incorporate palliative and supportive care specialists early in the treatment trajectory, focusing on pain and symptom management, communication, and emotional support to optimize the child's quality of life from day one.
MBBS, MD-Paediatric Medicine (1983), DM - Medical Oncology (1991)
Emeritus Professor & Senior ConsultantPaediatric Oncology and BMT
MBBS, MD-Paediatrics (2013), DM - Paediatric Oncology (2017)
Senior Consultant & HODPaediatric Oncology and BMT
MBBS, MD-Paediatrics (2016), MRCPCH (2019), HBNI Fellowship - Paediatric Hematology & Oncology (2023)
ConsultantPaediatric Oncology and BMT
MBBS, MD-Paediatrics (May 2021), DM - Paediatric Oncology (Nov 2025)
Junior ConsultantPaediatric Oncology and BMT
MBBS, DNB - Paediatrics (2017), DM - Paediatric Oncology (Mar 2025)
Junior ConsultantPaediatric Oncology and BMT
MBBS, MS (Gen Surgery), M.Ch (Paediatric Surgery), DNB
Visiting ConsultantPaediatric Oncology and BMT
MBBS, MS-Gen Surgery (2008), M.Ch - Paediatric Surgery (2011), Fellowship in Paediatric Minimally Invasive Surgery (2013)
Visiting ConsultantPaediatric Oncology and BMT
MBBS, MS-Gen Surgery (2015), M.Ch - Paediatric Surgery (2021)
Visiting ConsultantPaediatric Oncology and BMT
MBBS, DCH, MRCPCH
Paediatric Oncology and BMT
MBBS, MS-Gen Surgery (April 2015), M.Ch - Paediatric Surgery (July 2021), TMC Fellow in Paediatric Surgery (Sep 2023)
Visiting ConsultantPaediatric Oncology and BMT